StockData
Scribe Therapeutics, Inc. logo

Scribe Therapeutics, Inc. (SCTX) stock

SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$14.05−1.72 (-10.91%)

Close on Nov 18, 2026Market cap $34.92MP/E –Yield –

Scribe Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.48M–
Q1 FY2026Mar 31, 2026-$17.35M–
Q2 FY2025Jun 30, 2025-$9.90M–
Q1 FY2025Mar 31, 2025-$3.43M–

More Scribe Therapeutics figures

See a number that looks wrong?